Lamotrigine

CAS 84057-84-1 30 current records 8 historicalSmall Molecule

Who holds supplier records for Lamotrigine? 30 organisations hold a current record for Lamotrigine: an active US FDA Type II Drug Master File or a CEP. A further 8 organisations have only historical (inactive) DMF filings. 19 of them hold a valid EU Certificate of Suitability (20 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (19), China (2), Spain (2), Netherlands (1) and 3 other countries (3); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Lamotrigine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/lamotrigine

Reading the evidence

  • 30 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    19 of the 27 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 17 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Lamotrigine expires 14 Feb 2045. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (30)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Lamotrigine. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Lamotrigine sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (20)

Certificates of Suitability on the EDQM register for Lamotrigine, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 24 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
SMS PHARMACEUTICALS LIMITED HyderabadIN
CEP 2020-222 - Rev 02
Lamotrigine
Nov 2026—
COHANCE LIFESCIENCES LIMITED MumbaiIN
CEP 2008-261 - Rev 03
Lamotrigine
Jul 2026—
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2009-157 - Rev 04
Lamotrigine
May 2026—
IOL CHEMICALS AND PHARMACEUTICALS LIMITED LudhianaIN
CEP 2013-066 - Rev 02
Lamotrigine
Apr 2026—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2011-010 - Rev 06
Lamotrigine
Feb 2026—
ZYDUS LIFESCIENCES LIMITED VadodaraIN
CEP 2018-295 - Rev 04
Lamotrigine, Anhydrous Form
Jan 2026—
IPCA LABORATORIES LIMITED MumbaiIN
CEP 2018-293 - Rev 01
Lamotrigine
Dec 2025—
CTX LIFESCIENCES PVT. LIMITED SuratIN
CEP 2011-168 - Rev 03
Lamotrigine
Dec 2025—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2010-208 - Rev 03
Lamotrigine, Micronised and non-micronised
Oct 2025Inspected May 2026
Italy
JUBILANT BIOSYS LIMITED NanjangudIN
CEP 2009-162 - Rev 03
Lamotrigine
Sept 2025—
ARAGEN LIFE SCIENCES LIMITED HyderabadIN
CEP 2010-249 - Rev 07
Lamotrigine
Jul 2025—
TAPI NL B.V. AmsterdamNL
CEP 2011-178 - Rev 04
Lamotrigine
Mar 2025—
TORRENT PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2022-486 - Rev 00
Lamotrigine, Micronised
Nov 2024—
UNICHEM LABORATORIES LIMITED MumbaiIN
CEP 2009-376 - Rev 01
Lamotrigine
Nov 2024—
CIPLA LIMITED MumbaiIN
CEP 2010-212 - Rev 02
Lamotrigine
Mar 2024—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2008-010 - Rev 05
Lamotrigine
Jan 2024—
PHARMACEUTICAL WORKS POLPHARMA S.A. Starogard GdanskiPL
R1-CEP 2010-128 - Rev 02
Lamotrigine
Feb 2023—
COHANCE LIFESCIENCES LIMITED HyderabadIN
R0-CEP 2022-417 - Rev 00
Lamotrigine, Unit-II
Dec 2022—
Union Quimico Farmaceutica, S.A. (Uquifa S.A.) BarcelonaES
R1-CEP 2010-382 - Rev 04
Lamotrigine
Oct 2022—
ZHEJIANG SUPOR PHARMACEUTICALS CO., LTD. ShaoxingCN
R0-CEP 2020-249 - Rev 00
Lamotrigine
Mar 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (8)

Organisations whose Type II DMFs for Lamotrigine are no longer active. These show a past filing, not current supply.

Show all 8 historical records
  • WATERSTONE PHARMACEUTICALS HUBEI TIANMEN CO LTD
    Inactive DMF 25775 · filed Dec 2011
  • SEQUEL PHARMACHEM PRIVATE LTD
    Inactive DMF 22656 · filed Mar 2009
  • India · Inactive DMF 21390 · filed Mar 2008
  • Italy · Inactive DMF 21105 · filed Nov 2007
  • Apotex Pharmachem India Pvt. Ltd.
    India · Inactive DMF 20129 · filed Jan 2007
  • India · Inactive DMF 18356 · filed May 2005
  • Hungary · Inactive DMF 18353 · filed May 2005
  • CF PHARMA LTD
    Inactive DMF 18137 · filed Mar 2005

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (164 listed products contain Lamotrigine). The latest listed patent expires 14 Feb 2045. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Lamotrigine is an anticonvulsant medication used primarily to treat epilepsy and bipolar disorder. It works by stabilizing electrical activity in the brain to reduce seizures and mood swings.

Chemical identity

IUPAC name
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
Canonical SMILES
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
InChIKey
PYZRQGJRPPTADH-UHFFFAOYSA-N
Synonyms
Lamictal API, bw 430c, bw-430c, lamictal, nsc-759171, subvenite

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Anti-epileptic Agent; Mood Stabilizer
Mechanism of action
Dihydrofolate Reductase Inhibitors; Organic Cation Transporter 2 Inhibitors
Physiologic effect
Decreased Central Nervous System Disorganized Electrical Activity

Therapeutic areas

NeurologyPsychiatry

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Lamotrigine?

30 organisations hold an active US FDA Type II Drug Master File or a CEP for Lamotrigine: Iol Chemicals And Pharmaceuticals Limited (India), Alembic Pharmaceuticals Limited (India), APITORIA PHARMA PRIVATE LTD (India), Cipla Limited (India), COHANCE LIFESCIENCES LTD (India), JUBILANT BIOSYS LTD (India), MATRIX PHARMACORP PRIVATE LTD (India) and SMS Pharmaceuticals limited (India), and 22 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Lamotrigine Drug Master Files are active?

Iol Chemicals And Pharmaceuticals Limited (DMF 36531, 26627), Alembic Pharmaceuticals Limited (DMF 18732), APITORIA PHARMA PRIVATE LTD (DMF 19908), Cipla Limited (DMF 18421), COHANCE LIFESCIENCES LTD (DMF 16259, 23251), JUBILANT BIOSYS LTD (DMF 16142), MATRIX PHARMACORP PRIVATE LTD (DMF 17740) and SMS Pharmaceuticals limited (DMF 34290) and 16 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Lamotrigine records mean?

8 organisations have only inactive Type II DMFs for Lamotrigine. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Lamotrigine have a European Certificate of Suitability?

Yes. 19 organisations hold a valid CEP for Lamotrigine on the EDQM register, including SMS PHARMACEUTICALS LIMITED Hyderabad (IN), COHANCE LIFESCIENCES LIMITED Mumbai (IN), MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), IOL CHEMICALS AND PHARMACEUTICALS LIMITED Ludhiana (IN), ALEMBIC PHARMACEUTICALS LIMITED Vadodara (IN) and ZYDUS LIFESCIENCES LIMITED Vadodara (IN) and 14 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Lamotrigine?

Yes. The latest patent listed for an approved US product containing Lamotrigine expires 14 Feb 2045, across 164 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Lamotrigine supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Lamotrigine?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.